Ningbo Holly Arts & Crafts Co.,Ltd.
For more than 10 years activity at World Globe industry incubate Holly. At the beginning, we only can offer traditional hand-glued paper surface globe and single style, always do repeat job. To meet customer needs, young people try to change, source, discover, achieve...Then developed todays` more range, such as Illuminated World Globes, Eco-friendly Paperboard Globes, Decorative Desktop Globes, Large Size Floor Globes and Wall Maps.
Except to expand products range, also focused on quality and safety standards. Factory got BSCI report and ISO 9001-2008 certificate. Map be audited by official map bureau. Items with EN71-1/2/3, CE-EMC, CE-LVD, EU Phthalates, EU Cadmium, 16 CFR 1303 Lead in Surface Coating, Prop 65 Lead, Prop 65 Phthalates test report.
Sincere, Friendly and Cooperative. We continuously strive to improve our job be a good World Globe supplier.
Ningbo Holly Arts & Crafts Co.,Ltd.
For more than 10 years activity at World Globe industry incubate Holly. At the beginning, we only can offer traditional hand-glued paper surface globe and single style, always do repeat job. To meet customer needs, young people try to change, source, discover, achieve...Then developed todays` more range, such as Illuminated World Globes, Eco-friendly Paperboard Globes, Decorative Desktop Globes, Large Size Floor Globes and Wall Maps.
Except to expand products range, also focused on quality and safety standards. Factory got BSCI report and ISO 9001-2008 certificate. Map be audited by official map bureau. Items with EN71-1/2/3, CE-EMC, CE-LVD, EU Phthalates, EU Cadmium, 16 CFR 1303 Lead in Surface Coating, Prop 65 Lead, Prop 65 Phthalates test report.
Sincere, Friendly and Cooperative. We continuously strive to improve our job be a good World Globe supplier.
Ningbo Holly Arts & Crafts Co.,Ltd.
For more than 10 years activity at World Globe industry incubate Holly. At the beginning, we only can offer traditional hand-glued paper surface globe and single style, always do repeat job. To meet customer needs, young people try to change, source, discover, achieve...Then developed todays` more range, such as Illuminated World Globes, Eco-friendly Paperboard Globes, Decorative Desktop Globes, Large Size Floor Globes and Wall Maps.
Except to expand products range, also focused on quality and safety standards. Factory got BSCI report and ISO 9001-2008 certificate. Map be audited by official map bureau. Items with EN71-1/2/3, CE-EMC, CE-LVD, EU Phthalates, EU Cadmium, 16 CFR 1303 Lead in Surface Coating, Prop 65 Lead, Prop 65 Phthalates test report.
Sincere, Friendly and Cooperative. We continuously strive to improve our job be a good World Globe supplier.
Ningbo Holly Arts & Crafts Co.,Ltd.
For more than 10 years activity at World Globe industry incubate Holly. At the beginning, we only can offer traditional hand-glued paper surface globe and single style, always do repeat job. To meet customer needs, young people try to change, source, discover, achieve...Then developed todays` more range, such as Illuminated World Globes, Eco-friendly Paperboard Globes, Decorative Desktop Globes, Large Size Floor Globes and Wall Maps.
Except to expand products range, also focused on quality and safety standards. Factory got BSCI report and ISO 9001-2008 certificate. Map be audited by official map bureau. Items with EN71-1/2/3, CE-EMC, CE-LVD, EU Phthalates, EU Cadmium, 16 CFR 1303 Lead in Surface Coating, Prop 65 Lead, Prop 65 Phthalates test report.
Sincere, Friendly and Cooperative. We continuously strive to improve our job be a good World Globe supplier.
GE Healthcare is an innovator of global cutting-edge medical technology, diagnostic drugs and digital solutions. It is committed to making hospital operations more efficient, clinical diagnosis more effective, treatments more accurate, and patients healthier by providing integrated solutions, services, and data analysis. and happiness. In the more than 100 years of serving patients and medical institutions, GE Medical has continued to promote personalized, interconnected and more empathetic medical care, while simplifying the patient diagnosis and treatment process. GE Medical's medical imaging, ultrasound, life care and diagnostic drug business covers medical care in all aspects from diagnosis, treatment to monitoring. GE Medical was listed on the Nasdaq Stock Exchange in January 2023. The company's business covers more than 160 countries and regions. Since starting to serve Chinese patients in 1897, GE Medical has begun a century-long process of development in China. GE Medical established its China office in Beijing in 1986. In 1991, it jointly built a local factory "GE Hangwei" (Hangwei General Electric Medical Systems Co., Ltd.) with the former Ministry of Aerospace and the Ministry of Health. So far, it has been all over the country. It has more than 30 offices and has built three "creation centers" in Beijing, Wuxi and Shanghai. It has more than 7,000 employees and a local R&D team of about 1,800 people. Since 2011, it has led the research and development and marketed nearly 110 innovative products. In China, GE Medical has improved the accessibility of precision medicine and high-quality medical resources, and helped the construction of "Healthy China 2030". As one of the first multinational companies to start domestic layout, GE Medical has five major production bases (including six factories) in Beijing, Shanghai, Wuxi, Tianjin and Chengdu, and has built a "domestic" full coverage from universal and affordable to high-end. ability. GE Medical produces CT, X-ray machines, vascular machines, surgical machines and other imaging equipment in Beijing; builds a contrast agent production base in Shanghai; produces magnetic resonance imaging systems in Tianjin; produces ultrasound, anesthesia, electrocardiogram monitoring, and ventilators in Wuxi. , patient monitoring and other clinical nursing equipment. GE Medical's fifth production base in China is under construction in Chengdu; the production base of Sinopharm Devices and GE Medical Joint Venture is under construction in Shenzhen.
General Electric Company
GE Healthcare is an innovator of global cutting-edge medical technology, diagnostic drugs and digital solutions. It is committed to making hospital operations more efficient, clinical diagnosis more effective, treatments more accurate, and patients healthier by providing integrated solutions, services, and data analysis. and happiness. In the more than 100 years of serving patients and medical institutions, GE Medical has continued to promote personalized, interconnected and more empathetic medical care, while simplifying the patient diagnosis and treatment process. GE Medical's medical imaging, ultrasound, life care and diagnostic drug business covers medical care in all aspects from diagnosis, treatment to monitoring. GE Medical was listed on the Nasdaq Stock Exchange in January 2023. The company's business covers more than 160 countries and regions. Since starting to serve Chinese patients in 1897, GE Medical has begun a century-long process of development in China. GE Medical established its China office in Beijing in 1986. In 1991, it jointly built a local factory "GE Hangwei" (Hangwei General Electric Medical Systems Co., Ltd.) with the former Ministry of Aerospace and the Ministry of Health. So far, it has been all over the country. It has more than 30 offices and has built three "creation centers" in Beijing, Wuxi and Shanghai. It has more than 7,000 employees and a local R&D team of about 1,800 people. Since 2011, it has led the research and development and marketed nearly 110 innovative products. In China, GE Medical has improved the accessibility of precision medicine and high-quality medical resources, and helped the construction of "Healthy China 2030". As one of the first multinational companies to start domestic layout, GE Medical has five major production bases (including six factories) in Beijing, Shanghai, Wuxi, Tianjin and Chengdu, and has built a "domestic" full coverage from universal and affordable to high-end. ability. GE Medical produces CT, X-ray machines, vascular machines, surgical machines and other imaging equipment in Beijing; builds a contrast agent production base in Shanghai; produces magnetic resonance imaging systems in Tianjin; produces ultrasound, anesthesia, electrocardiogram monitoring, and ventilators in Wuxi. , patient monitoring and other clinical nursing equipment. GE Medical's fifth production base in China is under construction in Chengdu; the production base of Sinopharm Devices and GE Medical Joint Venture is under construction in Shenzhen.
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
AbbVie Inc.
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
AstraZeneca PLC
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
Roche Holding AG
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
Becton, Dickinson and Company
BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents.
Becton, Dickinson and Company
BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents.
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Johnson & Johnson
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Beijing Novartis Pharma Ltd.
Novartis ' history can be traced back to three companies that have intersections with it. Gargi established a trading of chemicals and dyes in Basel, Switzerland in the mid-18th century; Ciba began to produce dyes in 1859; Sandoz in 1886 2019 a chemical company was established in Basel. Later, Novartis was formed by the merger of these three companies in 1996. With its predecessor's long and rich experience in developing innovative products, it developed from its initial focus on the production and synthesis of fiber fabric dyes and became a focus on chemistry The world's largest pharmaceutical and health enterprise of product and medicine. Novartis is one of the three largest pharmaceutical companies in the world. Its headquarters is located in Basel, Switzerland. Its business covers more than 150 countries and regions around the world and has 138,000 employees. Novartis is committed to providing innovative medical and healthcare solutions to patients and society to meet their changing health needs, focusing on the four core therapeutic areas where patients need urgently (cardiovascular, kidney and metabolism, tumors, immune, neuroscience) and the five major Technology platforms (chemotherapy, biotherapy, xRNA therapy, radioligand therapy, gene and cell therapy) continue to develop pioneering therapies. It has a diversified product portfolio, with business departments including innovative drugs (Novartis), ophthalmic health care (Alcon), generic drugs (Sandus), vaccines, and animal health products. The Novartis China headquarters was established in 1997. Its name is "Promise for China", which means improving the health level and quality of life of the Chinese people through continuous innovative products and services. China is one of Novartis' major strategic markets around the world. Novartis has laid out its Chinese market from R&D, production to business development, and has built production bases in Changping, Beijing, and established R&D institutions in Beijing, Shanghai and Jiangsu. Since 1987, Novartis has approved about 100 innovative drugs and new indications in China. In order to accelerate the introduction of innovative drugs, since 2022, Novartis' new drugs and new indications in China have achieved 100% sync with the world; at the same time, Novartis actively promotes the accessibility of innovative drugs, and since 2017, more than 30 have been reported. The drug has been included in the national medical insurance catalog.
Beijing Novartis Pharma Ltd.
Novartis ' history can be traced back to three companies that have intersections with it. Gargi established a trading of chemicals and dyes in Basel, Switzerland in the mid-18th century; Ciba began to produce dyes in 1859; Sandoz in 1886 2019 a chemical company was established in Basel. Later, Novartis was formed by the merger of these three companies in 1996. With its predecessor's long and rich experience in developing innovative products, it developed from its initial focus on the production and synthesis of fiber fabric dyes and became a focus on chemistry The world's largest pharmaceutical and health enterprise of product and medicine. Novartis is one of the three largest pharmaceutical companies in the world. Its headquarters is located in Basel, Switzerland. Its business covers more than 150 countries and regions around the world and has 138,000 employees. Novartis is committed to providing innovative medical and healthcare solutions to patients and society to meet their changing health needs, focusing on the four core therapeutic areas where patients need urgently (cardiovascular, kidney and metabolism, tumors, immune, neuroscience) and the five major Technology platforms (chemotherapy, biotherapy, xRNA therapy, radioligand therapy, gene and cell therapy) continue to develop pioneering therapies. It has a diversified product portfolio, with business departments including innovative drugs (Novartis), ophthalmic health care (Alcon), generic drugs (Sandus), vaccines, and animal health products. The Novartis China headquarters was established in 1997. Its name is "Promise for China", which means improving the health level and quality of life of the Chinese people through continuous innovative products and services. China is one of Novartis' major strategic markets around the world. Novartis has laid out its Chinese market from R&D, production to business development, and has built production bases in Changping, Beijing, and established R&D institutions in Beijing, Shanghai and Jiangsu. Since 1987, Novartis has approved about 100 innovative drugs and new indications in China. In order to accelerate the introduction of innovative drugs, since 2022, Novartis' new drugs and new indications in China have achieved 100% sync with the world; at the same time, Novartis actively promotes the accessibility of innovative drugs, and since 2017, more than 30 have been reported. The drug has been included in the national medical insurance catalog.
Pocos International Medical Trading (Shanghai) Co., Ltd.
Boston Science continues to develop breakthrough medical technologies and products, contributing to the progress of multiple medical fields. Committed to reducing patient trauma, reducing medical costs, and effectively improving the quality of life. Boston Science currently owns more than 13,000 life-improving products, and the company invests more than $1 billion in research and development every year. Boston Science is committed to improving people's lives and improving the health quality of patients around the world through innovative medical solutions. Innovating for life is the mission of Boston Science and a commitment to patients, physicians and medical systems around the world. About 30 million patients benefit from Boston’s scientific innovative medical solutions each year.
Pocos International Medical Trading (Shanghai) Co., Ltd.
Boston Science continues to develop breakthrough medical technologies and products, contributing to the progress of multiple medical fields. Committed to reducing patient trauma, reducing medical costs, and effectively improving the quality of life. Boston Science currently owns more than 13,000 life-improving products, and the company invests more than $1 billion in research and development every year. Boston Science is committed to improving people's lives and improving the health quality of patients around the world through innovative medical solutions. Innovating for life is the mission of Boston Science and a commitment to patients, physicians and medical systems around the world. About 30 million patients benefit from Boston’s scientific innovative medical solutions each year.
Stryker (Beijing) Medical Devices Co., Ltd.
As one of the world's cutting-edge medical technology companies, Stryker works sincerely with customers and is committed to improving healthcare. The company provides a range of innovative products and services including plastic surgery, medical and surgical equipment, neurosurgery and spine-related products to help improve the treatment experience of patients and medical institutions. Dr. Homer Stryker, an orthopedic physician in Kalamazoo, Michigan, invented a series of new products after discovering that some medical products cannot meet the needs of patients. There is growing concern and interest in these new medical products, and Dr. Stryker founded The Orthopaedic Frame Company in 1941, specializing in the production of these innovative medical products. In 1942, the company began to build wedge-shaped turnover beds, which allow caregivers to turn over patients with severe back injuries while keeping their spine fixed; In 1946, Stryker founded The Orthopaedic Frame Company; In 1979, the company issued its shares for the first time, bringing more attention to the company; in the same year, Stryker acquired Osteonics Corp. and entered the orthopedic implant market; In 1981, the company's acquisition of SynOptics provided an opportunity to expand into its endoscope business; In 1992, the acquisition of Dimso, SA opened up business opportunities in the field of spinal fixation; In 1996, the acquisition of Osteo SA provided an opportunity to enter the bone trauma market; In 1997, 18 years after the company was listed on the Nasdaq, the company was listed on the New York Stock Exchange; In 1998, the company acquired Howmedica, a major player in the orthopedic market, and doubled its size in the coming year. In 2009, the company acquired Ascent Healthcare Solutions, Inc., a leading market leader in the U.S. medical device reprocessing and remanufacturing market; In 2011, the company acquired Boston Scientific's neurovascular division, greatly expanding the brand's neurotechnology business; In 2013, the company acquired Trauson Holdings Company Limited to expand into high-value market segments in emerging markets. In the same year, the company's acquisition of MAKO Surgical Corp provided an opportunity to further promote the development of robotic arm-assisted surgery in orthopedics.
Stryker (Beijing) Medical Devices Co., Ltd.
As one of the world's cutting-edge medical technology companies, Stryker works sincerely with customers and is committed to improving healthcare. The company provides a range of innovative products and services including plastic surgery, medical and surgical equipment, neurosurgery and spine-related products to help improve the treatment experience of patients and medical institutions. Dr. Homer Stryker, an orthopedic physician in Kalamazoo, Michigan, invented a series of new products after discovering that some medical products cannot meet the needs of patients. There is growing concern and interest in these new medical products, and Dr. Stryker founded The Orthopaedic Frame Company in 1941, specializing in the production of these innovative medical products. In 1942, the company began to build wedge-shaped turnover beds, which allow caregivers to turn over patients with severe back injuries while keeping their spine fixed; In 1946, Stryker founded The Orthopaedic Frame Company; In 1979, the company issued its shares for the first time, bringing more attention to the company; in the same year, Stryker acquired Osteonics Corp. and entered the orthopedic implant market; In 1981, the company's acquisition of SynOptics provided an opportunity to expand into its endoscope business; In 1992, the acquisition of Dimso, SA opened up business opportunities in the field of spinal fixation; In 1996, the acquisition of Osteo SA provided an opportunity to enter the bone trauma market; In 1997, 18 years after the company was listed on the Nasdaq, the company was listed on the New York Stock Exchange; In 1998, the company acquired Howmedica, a major player in the orthopedic market, and doubled its size in the coming year. In 2009, the company acquired Ascent Healthcare Solutions, Inc., a leading market leader in the U.S. medical device reprocessing and remanufacturing market; In 2011, the company acquired Boston Scientific's neurovascular division, greatly expanding the brand's neurotechnology business; In 2013, the company acquired Trauson Holdings Company Limited to expand into high-value market segments in emerging markets. In the same year, the company's acquisition of MAKO Surgical Corp provided an opportunity to further promote the development of robotic arm-assisted surgery in orthopedics.
Merck Investments (China) Co., Ltd.
Merck KGaA was founded in 1668 and has a history of about 350 years. It is headquartered in Darmstadt, Germany. It is mainly committed to innovative pharmaceuticals, life sciences and cutting-edge functional material technologies, and Technology is the driving force to create value for patients and customers. Merck began to engage in trade with China at the end of the 19th century, selling high-purity chemical reagents to China, and established a Chinese subsidiary in Shanghai in 1933. In China, Merck is mainly engaged in pharmaceutical, life sciences and chemical businesses, and provides customers with solutions from innovative prescription drugs, over-the-counter drugs to life sciences, effective pigments and chemicals for industrial purposes. Merck's business is mainly divided into four major branches: Merck Serono business branch, consumer health care business branch, Merck Millipo business branch, and functional materials business branch. Merck is a partner of China. Merck has a history of development in China for more than 80 years. China is an important strategic market for all Merck's business areas (including high-performance materials, life sciences and medical health); Merck has 3,200 employees in China (including Hong Kong and Macau); in Beijing, Shanghai, Hong Kong, Wuxi, Suzhou and Nantong has 20 corporate entities. Merck has many important investments in China. Recently, Merck's pharmaceutical, health and life sciences business in Nantong and its high-performance materials business in Shanghai have invested 170 million euros, 80 million euros and 44 million euros respectively. In addition, Merck has also set up a global biopharmaceutical R&D center in Beijing, a display material R&D center and a life science laboratory in Shanghai, and a lithographic material R&D center in Suzhou. China has become an important source of innovation for Merck.
Merck Investments (China) Co., Ltd.
Merck KGaA was founded in 1668 and has a history of about 350 years. It is headquartered in Darmstadt, Germany. It is mainly committed to innovative pharmaceuticals, life sciences and cutting-edge functional material technologies, and Technology is the driving force to create value for patients and customers. Merck began to engage in trade with China at the end of the 19th century, selling high-purity chemical reagents to China, and established a Chinese subsidiary in Shanghai in 1933. In China, Merck is mainly engaged in pharmaceutical, life sciences and chemical businesses, and provides customers with solutions from innovative prescription drugs, over-the-counter drugs to life sciences, effective pigments and chemicals for industrial purposes. Merck's business is mainly divided into four major branches: Merck Serono business branch, consumer health care business branch, Merck Millipo business branch, and functional materials business branch. Merck is a partner of China. Merck has a history of development in China for more than 80 years. China is an important strategic market for all Merck's business areas (including high-performance materials, life sciences and medical health); Merck has 3,200 employees in China (including Hong Kong and Macau); in Beijing, Shanghai, Hong Kong, Wuxi, Suzhou and Nantong has 20 corporate entities. Merck has many important investments in China. Recently, Merck's pharmaceutical, health and life sciences business in Nantong and its high-performance materials business in Shanghai have invested 170 million euros, 80 million euros and 44 million euros respectively. In addition, Merck has also set up a global biopharmaceutical R&D center in Beijing, a display material R&D center and a life science laboratory in Shanghai, and a lithographic material R&D center in Suzhou. China has become an important source of innovation for Merck.
Danaher (Shanghai) Corporate Management Co., Ltd.
Danaher is a global innovator in science and technology, committed to helping clients meet complex challenges around the world and improve their quality of life. When laboratory doctors perform routine blood tests on blood samples from patients with fever, when surgeons perform surgery on unborn fetuses, when food manufacturers minimize food waste in the supply chain, and when we want to protect humans on what they rely on for survival Water resources, you and I are creating influence for this world. When Beckman Coulter’s solution provides doctors with high-quality blood cell analysis results; when Leica microscope provides fine anatomy and bright lighting for surgery; when ESKO’s technology supports environmentally friendly packaging design, Reduce carbon footprint and extend food shelf life; when Hach (HACH) technology helps scientists monitor the water quality of lakes, rivers and oceans, protect global marine ecosystems, and at the same time, helps tap water plants monitor the production of high-quality drinking water, it will be safer The better taste of tap water is transported to thousands of households. As a member of Danaher, these companies from different fields and industries gather together for a common goal. Every day, more than 80,000 Danah people around the world create influence together to achieve unlimited potential in life. Danaher is committed to building a multinational group company driven by local innovation in China. Danaher China is headquartered in Shanghai. Its main operating companies have branches, manufacturing factories and R&D teams in China, bringing together more than 6,000 local talents to serve the Chinese market with innovative and internationally advanced localized solutions. At present, 13 factories have been invested and established in China and 17 R&D teams have been established. At the same time, after several years of hard work, Danaher has dozens of R&D projects from China to the world, benefiting the world. In addition, Danaher actively develops partners locally, builds new types of win-win partnerships within the ecosystem, improves the overall service capabilities of the industry, and creates greater value for society.
Danaher (Shanghai) Corporate Management Co., Ltd.
Danaher is a global innovator in science and technology, committed to helping clients meet complex challenges around the world and improve their quality of life. When laboratory doctors perform routine blood tests on blood samples from patients with fever, when surgeons perform surgery on unborn fetuses, when food manufacturers minimize food waste in the supply chain, and when we want to protect humans on what they rely on for survival Water resources, you and I are creating influence for this world. When Beckman Coulter’s solution provides doctors with high-quality blood cell analysis results; when Leica microscope provides fine anatomy and bright lighting for surgery; when ESKO’s technology supports environmentally friendly packaging design, Reduce carbon footprint and extend food shelf life; when Hach (HACH) technology helps scientists monitor the water quality of lakes, rivers and oceans, protect global marine ecosystems, and at the same time, helps tap water plants monitor the production of high-quality drinking water, it will be safer The better taste of tap water is transported to thousands of households. As a member of Danaher, these companies from different fields and industries gather together for a common goal. Every day, more than 80,000 Danah people around the world create influence together to achieve unlimited potential in life. Danaher is committed to building a multinational group company driven by local innovation in China. Danaher China is headquartered in Shanghai. Its main operating companies have branches, manufacturing factories and R&D teams in China, bringing together more than 6,000 local talents to serve the Chinese market with innovative and internationally advanced localized solutions. At present, 13 factories have been invested and established in China and 17 R&D teams have been established. At the same time, after several years of hard work, Danaher has dozens of R&D projects from China to the world, benefiting the world. In addition, Danaher actively develops partners locally, builds new types of win-win partnerships within the ecosystem, improves the overall service capabilities of the industry, and creates greater value for society.
Thermo Fisher Scientific (China) Co., Ltd.
Thermo Fisher Technology is a world leader in the field of scientific services, with annual sales exceeding US$30 billion. The company ’s mission is to help customers make the world healthier, cleaner and safer. Help customers accelerate research in the field of life sciences, solve complex problems and challenges encountered in the field of analysis, promote the development of medical diagnosis and treatment, and improve laboratory productivity. More than 80,000 Thermo Fisher employees around the world will provide customers with advanced innovative technologies, convenient procurement solutions and multi-faceted services through a series of industry-leading brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. Thermo Fisher Technology China In 1982, Thermo Fisher set up its first sales office in China, with its headquarters in Shanghai in China, and has established branches in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xi'an, Nanjing, Wuhan, Jinan, Dongguan and other places. . The products mainly include analytical instruments, laboratory equipment, reagents, consumables and software, etc., provide comprehensive laboratory solutions to serve customers from all walks of life. In order to meet the needs of the Chinese market, the current eight factories are operated in Shanghai, Beijing, Suzhou and Guangzhou respectively. 6 application development centers and demonstration laboratories have been established nationwide to bring world-leading technologies and products to Chinese customers, and provide many services such as application development and training; China Innovation Centers located in Shanghai and Suzhou have more than 100 Professional researchers and engineers and more than 100 patents. The Innovation Center focuses on product research and development in vertical markets, combining the needs of the Chinese market and advanced technologies at home and abroad, and develops technologies and products suitable for Chinese users.
Thermo Fisher Scientific (China) Co., Ltd.
Thermo Fisher Technology is a world leader in the field of scientific services, with annual sales exceeding US$30 billion. The company ’s mission is to help customers make the world healthier, cleaner and safer. Help customers accelerate research in the field of life sciences, solve complex problems and challenges encountered in the field of analysis, promote the development of medical diagnosis and treatment, and improve laboratory productivity. More than 80,000 Thermo Fisher employees around the world will provide customers with advanced innovative technologies, convenient procurement solutions and multi-faceted services through a series of industry-leading brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. Thermo Fisher Technology China In 1982, Thermo Fisher set up its first sales office in China, with its headquarters in Shanghai in China, and has established branches in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xi'an, Nanjing, Wuhan, Jinan, Dongguan and other places. . The products mainly include analytical instruments, laboratory equipment, reagents, consumables and software, etc., provide comprehensive laboratory solutions to serve customers from all walks of life. In order to meet the needs of the Chinese market, the current eight factories are operated in Shanghai, Beijing, Suzhou and Guangzhou respectively. 6 application development centers and demonstration laboratories have been established nationwide to bring world-leading technologies and products to Chinese customers, and provide many services such as application development and training; China Innovation Centers located in Shanghai and Suzhou have more than 100 Professional researchers and engineers and more than 100 patents. The Innovation Center focuses on product research and development in vertical markets, combining the needs of the Chinese market and advanced technologies at home and abroad, and develops technologies and products suitable for Chinese users.
Philips (China) Investment Co., Ltd.
Patients and medical care workers are the core of Philips' health care system. The services provided cross the boundaries of pure health care services and can provide users with a comprehensive and excellent health care service experience, which can greatly improve the patient's medical care effect and significantly reduce the Overall medical care costs. As a healthcare expert in heart disease, oncology, critical care and women, Philips is always committed to developing and providing healthcare solutions to provide users with value for money, ranging from disease prevention, radiation diagnosis to treatment, to Health management and monitoring, etc.
Philips (China) Investment Co., Ltd.
Patients and medical care workers are the core of Philips' health care system. The services provided cross the boundaries of pure health care services and can provide users with a comprehensive and excellent health care service experience, which can greatly improve the patient's medical care effect and significantly reduce the Overall medical care costs. As a healthcare expert in heart disease, oncology, critical care and women, Philips is always committed to developing and providing healthcare solutions to provide users with value for money, ranging from disease prevention, radiation diagnosis to treatment, to Health management and monitoring, etc.
Siemens Medical is a world-renowned medical technology company. For 130 years, it has led the innovation of medical technology. The company continues to develop innovative products and services, including artificial intelligence-based applications and digital products that play an increasingly important role in the development of the new generation of medical technology, and further consolidates the fields of in vitro diagnosis, image-guided treatment, in vivo diagnosis and new cancer diagnosis and treatment. The basis of At the same time, Siemens Medical provides a wide range of services and solutions to help medical service providers improve their capabilities and provide patients with high-quality and efficient services. In order to achieve the goal of "Siemens Medical 2025 Strategy", by accelerating business expansion, exploring growth markets related to core businesses such as artificial intelligence, future diagnosis and treatment or technical support services, and completing the next phase of the goal in a more targeted way and method. , further consolidate our market leadership position. In China, Siemens Medical is committed to becoming a trusted partner for China's medical and health system and Chinese patients by meeting the most pressing medical needs. The company has launched a new China strategy for the next three years, and will be "customer-centric" in all aspects, targeting the differentiated needs of different customer groups, establishing a more focused and professional team, and providing an overall solution driven by digitalization. , meet the needs of Chinese customers. In 2022, Siemens Medical China officially released the localization strategy of "National Intelligence Innovation", aiming to deeply participate in the construction of a healthy China as a Chinese company. The upgraded strategy is divided into three dimensions: First, the company will gradually promote the localization of the entire product line, further enrich and improve the product lineage, meet the diversified needs of Chinese customers and patients, and help the local industrial chain transform and upgrade. Second, based on the demand of the Chinese market, the company further deepens its innovation and research and development. On the one hand, it accelerates the implementation of global leading technologies in China, benefiting doctors and patients as soon as possible, and on the other hand, it continues to explore local innovation. Third, the company continues to promote the upgrading of local business models, improve the large-scale application of medical equipment in all fields of the disease process, gradually improve the industrial ecology, and explore and practice multi-dimensional medical and industrial collaborative innovation model.
Siemens Healthineers AG
Siemens Medical is a world-renowned medical technology company. For 130 years, it has led the innovation of medical technology. The company continues to develop innovative products and services, including artificial intelligence-based applications and digital products that play an increasingly important role in the development of the new generation of medical technology, and further consolidates the fields of in vitro diagnosis, image-guided treatment, in vivo diagnosis and new cancer diagnosis and treatment. The basis of At the same time, Siemens Medical provides a wide range of services and solutions to help medical service providers improve their capabilities and provide patients with high-quality and efficient services. In order to achieve the goal of "Siemens Medical 2025 Strategy", by accelerating business expansion, exploring growth markets related to core businesses such as artificial intelligence, future diagnosis and treatment or technical support services, and completing the next phase of the goal in a more targeted way and method. , further consolidate our market leadership position. In China, Siemens Medical is committed to becoming a trusted partner for China's medical and health system and Chinese patients by meeting the most pressing medical needs. The company has launched a new China strategy for the next three years, and will be "customer-centric" in all aspects, targeting the differentiated needs of different customer groups, establishing a more focused and professional team, and providing an overall solution driven by digitalization. , meet the needs of Chinese customers. In 2022, Siemens Medical China officially released the localization strategy of "National Intelligence Innovation", aiming to deeply participate in the construction of a healthy China as a Chinese company. The upgraded strategy is divided into three dimensions: First, the company will gradually promote the localization of the entire product line, further enrich and improve the product lineage, meet the diversified needs of Chinese customers and patients, and help the local industrial chain transform and upgrade. Second, based on the demand of the Chinese market, the company further deepens its innovation and research and development. On the one hand, it accelerates the implementation of global leading technologies in China, benefiting doctors and patients as soon as possible, and on the other hand, it continues to explore local innovation. Third, the company continues to promote the upgrading of local business models, improve the large-scale application of medical equipment in all fields of the disease process, gradually improve the industrial ecology, and explore and practice multi-dimensional medical and industrial collaborative innovation model.
Abbott Trading (Shanghai) Co., Ltd.
In 1888, Abbott Pharmaceutical Factory was founded in Chicago, USA by its founder, Dr. Wallace C. Abbott, to help people in more than 160 countries and regions around the world live a wonderful life. Abbott has been operating in China as early as the 1930s and has been operating since 1988. Abbott is rooted in China and continues to expand its market. In the past 30 years, it has provided Chinese consumers with a variety of nutritional products, medicines and medical products. At present, in addition to establishing a Chinese headquarters in Shanghai, Abbott has also established 16 offices, 4 factories and 2 R&D centers, with more than 6,000 employees. Abbott develops, produces and distributes products covering nutritional products, medicines, medical devices and diagnostic products. Products and services meet the needs of many aspects from disease prevention to diagnosis, treatment to recovery, and are based on local needs to achieve common health goals. Since 2010, Abbott has continued to invest in the Chinese market, developing, producing and distributing products in China, covering nutritional products, medicines, medical devices and diagnostic products, products and services that can meet the needs of disease prevention to diagnosis and treatment to recovery. . In 2014, the advanced nutritional products factory established in Jiaxing with an investment of US$230 million was officially opened. This is a major investment project in China, showing Abbott's strong attempt to improve the health of all Chinese people. Abbott attaches importance to China's local R&D capabilities, not only establishes R&D centers in Shanghai, but also establishes Shanghai Children's Medical Center with partners. Through local clinical trials and operations, Abbott China's R&D capabilities have been greatly improved. In terms of medical innovation, Abbott China has worked together with other R&D centers around the world to jointly respond to global medical problems. Abbott believes in the potential of life and continues to launch high-quality products and services, ranging from newborns to adults, from nutrition and diagnostics to health care and medical treatment. Abbott's passion and care make science an inexhaustible spring for a healthy life, committed to stimulating everyone's potential and pursuing a healthier and better life.
Abbott Trading (Shanghai) Co., Ltd.
In 1888, Abbott Pharmaceutical Factory was founded in Chicago, USA by its founder, Dr. Wallace C. Abbott, to help people in more than 160 countries and regions around the world live a wonderful life. Abbott has been operating in China as early as the 1930s and has been operating since 1988. Abbott is rooted in China and continues to expand its market. In the past 30 years, it has provided Chinese consumers with a variety of nutritional products, medicines and medical products. At present, in addition to establishing a Chinese headquarters in Shanghai, Abbott has also established 16 offices, 4 factories and 2 R&D centers, with more than 6,000 employees. Abbott develops, produces and distributes products covering nutritional products, medicines, medical devices and diagnostic products. Products and services meet the needs of many aspects from disease prevention to diagnosis, treatment to recovery, and are based on local needs to achieve common health goals. Since 2010, Abbott has continued to invest in the Chinese market, developing, producing and distributing products in China, covering nutritional products, medicines, medical devices and diagnostic products, products and services that can meet the needs of disease prevention to diagnosis and treatment to recovery. . In 2014, the advanced nutritional products factory established in Jiaxing with an investment of US$230 million was officially opened. This is a major investment project in China, showing Abbott's strong attempt to improve the health of all Chinese people. Abbott attaches importance to China's local R&D capabilities, not only establishes R&D centers in Shanghai, but also establishes Shanghai Children's Medical Center with partners. Through local clinical trials and operations, Abbott China's R&D capabilities have been greatly improved. In terms of medical innovation, Abbott China has worked together with other R&D centers around the world to jointly respond to global medical problems. Abbott believes in the potential of life and continues to launch high-quality products and services, ranging from newborns to adults, from nutrition and diagnostics to health care and medical treatment. Abbott's passion and care make science an inexhaustible spring for a healthy life, committed to stimulating everyone's potential and pursuing a healthier and better life.
Medtronic (Shanghai) Management Co., Ltd.
Because of extraordinary technology, life is facing severe health challenges, Medtronic uses advanced medical technology to bring extraordinary life experience to patients and inspire hope and possibilities in people's lives. Every day, many people face severe health challenges, but ordinary life is a luxury for them. When a type I diabetic patient went out to a friend's house, his father often worried about his son's blood sugar soaring; a woman with an arrhythmia was worried all day long. Some things that seem natural to ordinary people are troubled and struggled by. As a global medical technology company, Medtronic has expectations and strives to achieve more possibilities through innovation and its own profession, bringing patients an extraordinary life experience. Medtronic is committed to solving the complex challenges facing today's healthcare systems, and its business has expanded to more than 70 key disease areas. Medtronic acts quickly and seizes the day to serve more patients around the world with medical technology. Introduce data, artificial intelligence, automation technologies based on patient needs – turning insights into actions to make continuous improvements to the healthcare system. We hope to use technology to ignite the hope of life for patients and bring new possibilities. Medtronic operates in more than 150 countries and regions and has more than 90,000 employees worldwide. We expand access and strive to create more positive impacts beyond our own products. We are committed to promoting inclusion, diversity and equity, and we are committed to protecting our planet to create better results for all.
Medtronic (Shanghai) Management Co., Ltd.
Because of extraordinary technology, life is facing severe health challenges, Medtronic uses advanced medical technology to bring extraordinary life experience to patients and inspire hope and possibilities in people's lives. Every day, many people face severe health challenges, but ordinary life is a luxury for them. When a type I diabetic patient went out to a friend's house, his father often worried about his son's blood sugar soaring; a woman with an arrhythmia was worried all day long. Some things that seem natural to ordinary people are troubled and struggled by. As a global medical technology company, Medtronic has expectations and strives to achieve more possibilities through innovation and its own profession, bringing patients an extraordinary life experience. Medtronic is committed to solving the complex challenges facing today's healthcare systems, and its business has expanded to more than 70 key disease areas. Medtronic acts quickly and seizes the day to serve more patients around the world with medical technology. Introduce data, artificial intelligence, automation technologies based on patient needs – turning insights into actions to make continuous improvements to the healthcare system. We hope to use technology to ignite the hope of life for patients and bring new possibilities. Medtronic operates in more than 150 countries and regions and has more than 90,000 employees worldwide. We expand access and strive to create more positive impacts beyond our own products. We are committed to promoting inclusion, diversity and equity, and we are committed to protecting our planet to create better results for all.
